Dr. Landovitz is chief of the Division of Infectious Diseases in the Department of Medicine at the David Geffen School of Medicine, University of California, Los Angeles. He also serves as the director of the UCLA Center for Clinical AIDS Research and Education (CARE) and the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). As one of the protocol chairs for HPTN 077 and HPTN 083, Dr. Landovitz helped lead the NIH-funded trials that supported the 2021 FDA approval of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis (PrEP). He is also the chair of the HPTN Manuscript Review Committee, an HPTN Executive Committee member, and an HPTN Biomedical Sciences Working Group member. In December 2025, Dr. Landovitz assumed the role of co-principal investigator of the HIV Prevention Trials Network (HPTN).
